At the beginning of 2024, self-proclaimed tobacco- and nicotine-free pouches became available on the European market. Upon chemical analysis of different samples, it was demonstrated that these pouches were indeed devoid of nicotine but contained the synthetic nicotine homolog 6-methyl nicotine (6-MN) and this up to 20-mg 6-MN per pouch for the highest strengths, a molecule for which information is scarce, but yet, a part of a likely unaware/misled young adult subpopulation has easy access to these products.

ABSTRACT

A new nicotine delivery system in the form of tobacco-free nicotine pouches was introduced in Europe in 2019. These nicotine bags did not fall under the Tobacco Products Directive (TPD) II, which brought forward regulatory requirements for both cigarettes, related products, and e-liquids. As these pouches did not fall under the scope of the TPD, it was up to the member states to decide which action to be taken if any. Some EU member states banned these nicotine pouches, while others put restrictions on the amount of nicotine, warning messages, and presentation and packaging of the product, and some member states did not take any action. Likely as a result of the ban or restrictions, soon after also, tobacco and nicotine-free pouches became available in the European Union (EU). Early 2024, “NoNIC” pouches, claiming to be tobacco- and nicotine-free, became available on the European market. These pouches are promoted online and clearly target a younger population with a youth-appealing package design and enticing flavors. Upon analysis of different samples utilizing gas chromatography coupled to MS (GC–MS), liquid chromatography coupled to high-resolution tandem mass spectrometry (HRAM LC–MS2), and nuclear magnetic resonance spectroscopy (NMR), it was demonstrated that these pouches were indeed devoid of nicotine but contained the synthetic nicotine homolog 6-methyl nicotine (6-MN) and this up to 20 mg per pouch. Nonetheless, a part of a likely unaware/misled young adult subpopulation has easy access to these products, containing a novel molecule for which limited to no clinical effects are known.